JenPlateau said:

Receptor pharmacology relevant to the pharmacology: semaglutide is a GLP-1R agonist with a C-18 fatty acid chain that enables albumin binding (>99%),…

Bookmarking. The distinction being drawn above is the one nobody else makes. Taking it to my next appointment.

From the other side of the consultation, briefly. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

Ask again with the specifics and you will get a better answer than this one.

hyun_seoul said:

I want to add the drug interaction perspective on the pharmacology.

This is where I part company with the consensus forming above. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Moderator note: a couple of off-topic posts removed. Tagging this one for the weekly digest.